Keyword: Imfinzi (durvalumab)
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
Pascal Soriot’s reign at AstraZeneca is once again rumored to be coming to an end, and the company has reportedly begun looking for his successor.
AstraZeneca spent the last 16 months trying to keep investors’ hopes alive that its Mystic trial could succeed after an initial flop. But it didn’t.
AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.
AstraZeneca already has an Imfinzi OK in lung cancer maintenance. But new survival data will strengthen its case—and its lead over its I-O rivals.
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.
AstraZeneca's CEO knows he keeps saying the same thing, but once again, he had just one message for investors Thursday: Hang in there.
Imfinzi already is I-O's only FDA-approved maintenance therapy in lung cancer. Friday, the AZ med hit another benchmark to stretch out that lead.
Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.